01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...
00:22 , Dec 22, 2018 |  BioCentury  |  Finance

Venture surge

Venture capital investments in the life sciences surged to more than $20 billion worldwide in 2018, with VCs increasingly concentrating their disbursements in nine-digit megarounds, some of which preceded IPOs later in the year. Through...
20:20 , Dec 21, 2018 |  BC Week In Review  |  Company News

Merck KGaA puts CAR T development in Intrexon's hands

Merck KGaA (Xetra:MRK) has become the latest pharma to realize early stage CAR T technologies may be best in the hands of smaller companies after transferring to Intrexon Corp. (NYSE:XON) development rights for partnered CAR...
22:54 , Dec 20, 2018 |  BC Extra  |  Company News

Merck KGaA puts CAR T development in Intrexon's hands

Merck KGaA (Xetra:MRK) has become the latest pharma to realize early stage CAR T technologies may be best in the hands of smaller companies after transferring to Intrexon Corp. (NYSE:XON) development rights for partnered CAR...
22:36 , Dec 7, 2018 |  BioCentury  |  Finance

Taking Tesaro

While the $5.1 billion takeout price for Tesaro Inc. (NASDAQ:TSRO) is a far cry from its $9.8 billion peak valuation, investors who spoke with BioCentury see the final price tag as a fair value. GlaxoSmithKline...
22:07 , Dec 3, 2018 |  BC Extra  |  Company News

NIH may give ElevateBio exclusive CAR T license

NIH's National Cancer Institute is considering granting ElevateBio LLC (Cambridge, Mass.) an exclusive license to develop an undisclosed CAR T therapy targeting FMS-like tyrosine kinase 3 (FLT3; CD135). In a Federal Registry notice , NIH...
03:50 , Dec 1, 2018 |  BioCentury  |  Product Development

Cell therapy momentum at ASH

This year’s American Society of Hematology (ASH) meeting will showcase a surge in clinical CAR T cell presentations. But gene therapies are not following the same trajectory, despite both modalities being fresh off their first...
15:59 , Nov 16, 2018 |  BC Week In Review  |  Financial News

At $500M, Moderna files to raise record IPO

mRNA company Moderna Therapeutics Inc. (Cambridge, Mass.) filed on Nov. 9 to raise $500 million in an IPO on NASDAQ, which would mark the largest IPO on the exchange for a development stage biotech. Flagship...
01:39 , Nov 10, 2018 |  BC Extra  |  Financial News

At $500M, Moderna files to raise record IPO

mRNA company Moderna Therapeutics Inc. (Cambridge, Mass.) filed to raise $500 million in an IPO on NASDAQ, which would mark the largest IPO on the exchange for a development stage biotech. Flagship Pioneering launched Moderna...
17:27 , Nov 9, 2018 |  BC Week In Review  |  Financial News

Perceptive doubles up for second debt fund

Perceptive Advisors LLC closed on Nov. 5 its second debt fund, Perceptive Credit Opportunities Fund II, at $675 million, above its $500 million target. The figure is twice that of its first debt fund, which...